HCA
CCCC icon

Harbor Capital Advisors’s C4 Therapeutics CCCC Stock Holding History

Harbor Capital Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-96,964
Closed -$792K – 735
2024
Q1 		$792K Buy
96,964
+21,170
+28% +$164K 0.1% 270
2023
Q4 		$428K Buy
75,794
+5,091
+7% +$11.6K 0.08% 263
2023
Q3 		$132K Buy
70,703
+12,056
+21% +$36.8K 0.03% 399
2023
Q2 		$161K Buy
58,647
+5,369
+10% +$17.3K 0.03% 382
2023
Q1 		$167K Buy
53,278
+28,345
+114% +$167K 0.05% 207
2022
Q4 		$147K Sell
24,933
-537
-2% -$4.45K 0.14% 80
2022
Q3 		$223K Buy
25,470
+1,156
+5% +$12K 0.2% 81
2022
Q2 		$183K Buy
24,314
+2,446
+11% +$21.5K 0.14% 84
2022
Q1 		$531K Sell
21,868
-5,923
-21% -$144K 0.25% 76
2021
Q4 		$895K Buy
+27,791
New +$1.1M 0.33% 77

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Harbor Capital Advisors's CCCC Position: Q2 2024 in Review

Harbor Capital Advisors sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 96,964 shares — an estimated $792K sold.

Harbor Capital Advisors first reported a position in CCCC in Q4 2021 and held it in 10 quarters. The position peaked at $895K in Q4 2021. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

  • Harbor Capital Advisors reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 96,964 C4 Therapeutics shares in Q2 2024, an estimated $792K.
  • Harbor Capital Advisors first reported a position in C4 Therapeutics in Q4 2021 and held it in 10 quarters.
  • Harbor Capital Advisors's C4 Therapeutics position peaked at $895K in Q4 2021.
  • 115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.